LY2828360 is primarily investigated for its potential therapeutic applications in the field of oncology. It functions as a selective inhibitor of Aurora A kinase, an enzyme that plays a critical role in controlling cell division and is often overexpressed in certain cancers. By targeting Aurora A kinase, it aims to disrupt the growth and proliferation of malignant cells, offering a promising approach for the treatment of various cancers, particularly those involving abnormalities in cell division processes. Research is ongoing to evaluate its efficacy and safety in clinical trials, especially in cancers where traditional therapies have shown limited success. Additionally, preliminary studies suggest potential efficacy in other cancers related to cell division dysregulation. Its mechanism of action is being studied to explore its potential in combination therapies, enhancing the overall effectiveness of cancer treatment regimens.